Method
Level · gp.fundamentals.debt_to_revenue
Raw value 83.86% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTArcutis Biotherapeutics, Inc.'s latest supported as-filed period reports revenue of $129.9M. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 83.86% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.12% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 9.73% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 59.33% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 29.94% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 91.58% · CORE
Level · gp.fundamentals.operating_margin
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Inventory increased 138.2%; Inventory / revenue moved 991 bp higher.
2 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 59.3%; Operating margin moved 3058 bp higher; Operating income changed across a sign change.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Capital expenditure increased 102.6%; Capex / revenue moved 3 bp higher.
2 evidence-backed componentsCash & equivalents changed -53.1% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
ARQT · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001628280-26-061444SEC ↗4Aug 28, 2026Period Aug 27, 20260001628280-26-059444SEC ↗4Aug 24, 2026Period Aug 20, 20260001628280-26-058648SEC ↗4Aug 21, 2026Period Aug 19, 20260001628280-26-058420SEC ↗4Aug 19, 2026Period Aug 17, 20260001628280-26-058008SEC ↗4Aug 13, 2026Period Aug 11, 20260001628280-26-056898SEC ↗4Aug 5, 2026Period Aug 3, 20260001628280-26-053755SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 8, 2026Filed Sep 10, 2026 | Matsuda MasaruSee Remarks | Open Market SaleDirect | 9,989 | $25 | $249,986 | Form 4 ↗ |
| Aug 27, 2026Filed Aug 28, 2026 | Curran TerrieDirector | Option ExerciseDirect | 11,148 | $8 | $83,721 | Form 4 ↗ |
| Aug 27, 2026Filed Aug 28, 2026 | Curran TerrieDirector | Open Market SaleDirect | 11,148 | $25 | $279,028 | Form 4 ↗ |
| Aug 27, 2026Filed Aug 28, 2026 | Curran TerrieDirector | Option ExerciseDirect | 27,052 | $9 | $233,459 | Form 4 ↗ |
| Aug 27, 2026Filed Aug 28, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 12.65% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 15.67% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 9.83% · OPTIONAL
Current assets changed +40.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Inventory changed +138.2% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Net debt changed +111.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Total assets changed +38.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Working capital changed +34.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Cash / debt changed -3599 basis points from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001628280-26-053754| Curran TerrieDirector |
| Open Market SaleDirect |
| 27,052 |
| $25 |
| $677,095 |
| Form 4 ↗ |
| Aug 27, 2026Filed Aug 28, 2026 | Curran TerrieDirector | Option ExerciseDirect | 11,148 | $0 | $0 | Form 4 ↗ |
| Aug 27, 2026Filed Aug 28, 2026 | Curran TerrieDirector | Option ExerciseDirect | 27,052 | $0 | $0 | Form 4 ↗ |
| Aug 20, 2026Filed Aug 24, 2026 | Curran TerrieDirector | Option ExerciseDirect | 1,072 | $8 | $8,051 | Form 4 ↗ |
| Aug 20, 2026Filed Aug 24, 2026 | Curran TerrieDirector | Open Market SaleDirect | 1,072 | $26 | $27,912 | Form 4 ↗ |
| Aug 20, 2026Filed Aug 24, 2026 | Curran TerrieDirector | Option ExerciseDirect | 1,072 | $0 | $0 | Form 4 ↗ |
| Aug 19, 2026Filed Aug 21, 2026 | Burnett PatrickSee Remarks | Open Market SaleDirect | 1,697 | $27 | $45,819 | Form 4 ↗ |
| Aug 17, 2026Filed Aug 19, 2026 | Welgus Howard G.Director | Option ExerciseDirect | 822 | $7 | $5,361 | Form 4 ↗ |
| Aug 17, 2026Filed Aug 19, 2026 | Welgus Howard G.Director | Option ExerciseDirect | 1,019 | $8 | $7,653 | Form 4 ↗ |
| Aug 17, 2026Filed Aug 19, 2026 | Welgus Howard G.Director | Option ExerciseDirect | 2,255 | $9 | $19,461 | Form 4 ↗ |
| Aug 17, 2026Filed Aug 19, 2026 | Welgus Howard G.Director | Open Market SaleDirect | 4,730 | $26 | $123,835 | Form 4 ↗ |
| Aug 17, 2026Filed Aug 19, 2026 | Welgus Howard G.Director | Option ExerciseDirect | 822 | $0 | $0 | Form 4 ↗ |
| Aug 17, 2026Filed Aug 19, 2026 | Welgus Howard G.Director | Option ExerciseDirect | 1,019 | $0 | $0 | Form 4 ↗ |
| Aug 17, 2026Filed Aug 19, 2026 | Welgus Howard G.Director | Option ExerciseDirect | 2,255 | $0 | $0 | Form 4 ↗ |
| Aug 12, 2026Filed Aug 13, 2026 | Burnett PatrickSee Remarks | Option ExerciseDirect | 6,700 | $4 | $24,388 | Form 4 ↗ |
| Aug 12, 2026Filed Aug 13, 2026 | Burnett PatrickSee Remarks | Open Market SaleDirect | 6,700 | $26 | $174,767 | Form 4 ↗ |